GENTAUR Belgium BVBA BE0473327336 Voortstraat 49, 1910 Kampenhout BELGIUM Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc,Logistics 547 Yurok Circle, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, [email protected]

Index / Bioquant / Cancer markers: CA 19-9,ELISA kit /Product Detail : BQ 1017T Cancer markers: CA 19-9,ELISA kit
Related keywords:

#BQ 1017T

Cancer markers: CA 19-9,ELISA kit

 Price: 503   EUR
571   USD
390   GBP

Product name : Cancer markers: CA 19-9,ELISA kit

Catalog number : BQ 1017T

Quantity: 96 tests

Availability: Yes

Supplier name : Bioquant

Data sheet Data sheet : Ask more or other datasheet now !

About this Product :

Cancer markers: CA 19-9,ELISA kit
opis kitu
## product_name ## Służy do wykrywania białek w badanym materiale z użyciem przeciwciał poliklonalnych lub monoklonalnych skoniugowanych z odpowiednim enzymem

More Details about

Quantity 96 Well Plate
Sample Type Serum
Description
The CA 19-9 ELISA test system is an enzyme-linked immunosorbent assay (ELISA) for the quantitative determination of the Cancer Antigen CA 19-9 concentration in human serum. A group of mucin type glycoprotein Sialosyl Lewis Antigens (SLA), such as CA19-9 and CA19-5, have come to be recognized as circulating cancer associated antigens for gastrointestinal cancer. CA19-9 represents the most important and basic carbohydrate tumor marker. The immunohistologic distribution of CA19-9 in tissues is consistent with the quantitative determination of higher CA19-9 concentrations in cancer than in normal or inflamed tissues. Recently reports indicates that the serum CA19-9 level is frequently elevated in the serum of subjects with various gastrointestinal malignancies, such as pancreatic, colorectal, gastric and hepatic carcinomas. Together with CEA, elevated CA19-9 is suggestive of gallbladder neoplasm in the setting of inflammatory gallbladder disease. This tumor-associated antigen may also be elevated in some non-malignant conditions. Research studies demonstrate that serum CA 19-9 values may have utility in monitoring subjects with the above-mentioned diagnosed malignancies. It has been shown that a persistent elevation in serum CA19-9 value following treatment may be indicative of occult metastatic and/or residual disease. A persistently rising serum CA 19-9 value may be associated with progressive malignant disease and poor therapeutic response. A declining CA 19-9 value may be indicative of a favorable prognosis and good response to treatment.
Species Human

 

Contact us about this product :

Our team will respond you as soon as possible !

Email:
Name:
Phone:
Question, Comment :